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Metallobiology of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine neurotoxicity
Dominic J. Hare,w*ab Paul A. Adlard,b Philip A. Dobleza and David I. Finkelsteinb
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a potent toxin used to selectively destroy
dopaminergic neurons in the substantia nigra and induce parkinsonism. MPTP is metabolised to the
1-methyl-4-phenylpyridinium ion (MPP+) in glia, after which it enters the neuron via the dopamine
transporter and results in elevated levels of oxidative stress. The mechanism through which MPP+ causes
cell death is thought to involve redox-active metals, particularly iron (Fe). This review will examine how
cellular metal metabolism is altered following MPTP insult, and how this relates to metal dyshomeostasis
in idiopathic Parkinson’s disease. This includes both cell damage arising from increased metal
concentration, and how metal-binding proteins respond to MPTP-induced neurotoxicity. Implications for
using MPTP as a model for human Parkinson’s disease will be discussed in terms of cell metallobiology.
Introduction
Globally, Parkinson’s disease (PD) is the second most common
neurodegenerative disorder after Alzheimer’s disease, aﬀecting
around 1% of people aged 60 years and older.1 PD was first
described by James Parkinson in 1817, who reported on symp-
toms including tremor, poor posture and muscle loss in six
individuals.2 Traditionally the motor symptoms of PD, including
rigidity, tremors and bradykinesia, were thought of as the
cardinal features of the disease. PD is more commonly con-
sidered a syndrome that encompasses other symptoms such as
cognitive loss, sleep disturbances, loss of the ability to smell
and gastrointestinal problems. PD is characterised by the loss
of dopaminergic neurons of the substantia nigra (SN) pars
compacta (SNpc), noradrenergic neurons in the locus coeruleus
and the accumulation of insoluble protein inclusions known as
Lewy bodies throughout the basal ganglia, which eventually
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spread from within the medulla oblongata through to the
neocortex in six pathological stages.3 A feature of PD is abnormal
metal homeostasis within specific regions of the brain involved
in the disease. Atypical brain metal concentrations in human
PD brain tissue were first reported by Lhermitte et al.4 in 1924,
who commented on abnormal histological deposits of redox-
active iron (Fe) in the globus pallidus of a 53-year old male with
PD. Increases in both Fe and zinc (Zn) and a decrease in copper
(Cu) levels have since been observed in PD-aﬀected SN.5,6
Serum Fe has been observed to decrease in PD patients,7
though no change in serum Cu and Zn has been identified.8
Elevated brain Fe is a generally accepted consequence of
aging, with the more focal Fe accumulation occurring in
regions of the brain considered at risk of neurodegeneration,9
including those aﬀected by PD. Elevated Fe levels in the SN
has thus become an important target in PD research.10 Hyper-
echogenicity of the SN, measurable through ultrasonography,
has been associated with increased nigral Fe and microglial
activation in PD.11 Preliminary studies of a large cross-sectional
group of subjects found that 8 otherwise healthy adults dis-
playing hyperechogenicity had developed clinical PD symptoms
in follow-up consultations, suggesting hyperechogenicity, and
therefore elevated nigral Fe levels were present prior to physical
manifestation of the clinical defined disease.12 Thus, it is becoming
more widely accepted that deriving the association between metal
dyshomeostasis and PD progression is an important step in under-
standing both the cause of disease and developing therapeutics.
Significant attention is being paid to examining metallobiology in
both human PD and the various Parkinsonian animal models used
to study disease aetiology. A successful Parkinsonian model must
thus mimic the metal dyshomeostasis of idiopathic PD in addition
to other typical pathological features in order to provide a
complete model of disease. This review will focus upon
metal metabolism in one of the primary research tools utilised
for PD research: the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) toxin model.
Metals and MPTP toxicity: cause or eﬀect?
J. William Langston’s pioneering work in the 1980s13 paved the
way for the widespread use of MPTP as an in vivo neurotoxin
that recapitulates some aspects of the neuronal loss observed in
PD. The acute neurotoxicity was first described in detail after a
number of drug users developed L-3,4-dihydroxyphenylalanine-
(L-DOPA) responsive PD symptoms after administering the
synthetic opioid 1-methyl-4-phenyl-4-propionoxypiperidine
contaminated with 3% MPTP, which was confirmed by post
mortem identification of lesions in the SN.14 The subsequent
symptoms, disease progression and pathology of these people
was indistinguishable from the sporadic form of the disease
and as such has initiated its use in research.15 Jackson-Lewis
and Przedborski16 identified this, along with the relative ease of
administration compared to other candidates and the
consistent lesion as the major reasons MPTP is commonly chosen
for PD research. The MPTP model still engenders controversy
regarding the applicability of the results to the human condition,
mainly as the toxin does not illicit all the symptoms or the
progressive nature of the human disease. Irrespective of this,
MPTP provides the most complete model of nigrostriatal cell
death that can be studied en masse in the laboratory setting.
MPTP neurotoxicity arises from the formation of the toxic
1-methyl-4-phenylpyridinium (MPP+) metabolite.17 Monoamine
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oxidase (MAO) activity in glia converts MPTP to 1-methyl-4-
phenyl-2,3-dihydropyridinium (MPDP+), which rapidly dismutases
into MPP+.18 Like rotenone ((2R,6aS,12aS)-1,2,6,6a,12,12a-hexa-
hydro-2-isopropenyl-8,9-dimethoxychromeno[3,4-b]furo(2,3-h)-
chromen-6-one) and paraquat (N,N0-dimethyl-4,4 0-bipyridinium
dichloride), MPP+ accumulates in mitochondria, where it is a
potent complex I inhibitor, interfering with the first step of the
electron transport chain, decreasing cellular ATP production, inhi-
biting mitochondrial enzymes and increasing the synthesis of
reactive oxygen species (ROS).19–21 Importantly, complex I inhibi-
tion is a feature of MPP+ toxicity mirrored in idiopathic PD.22,23
MPP+ also stimulates increased ROS formation in the cyto-
plasm, independent of mitochondrial inhibition,24 suggesting the
mechanism of cell death is multifaceted. Cell damage resulting
from ROS is promoted by the presence of redox-active metals,
such as Fe, which mediate the formation of harmful hydrogen
peroxide and hydroxyl radicals via Fenton chemistry.25 Changes in
metal levels and metabolism following MPTP-induced neurotoxi-
city are an important hallmark of the toxin that appears to mirror
metal dyshomeostasis in humans, and taken together suggest the
role of metals in dopaminergic cell death. The role of metals in
MPTP-induced neuron loss was first discussed by Poirier et al.,26
who found that MPTP and high concentrations of transition
metals potentiate autoxidation of dopamine (DA) through
increased production of reactive oxygen species (ROS). The fact
that DA-rich neurons are more susceptible to cell death in both
PD and MPTP-treated cells suggests that DA catabolism plays a
major role. Autoxidation of DA occurs through two pathways: (i)
MAO on the surface of mitochondria coverts DA to an aldehyde
intermediate that is further metabolised to 3,4-dihydroxyphenyl-
acetic acid, or DOPAC; and (ii) oxidation of the catechol moiety
forms an electron-deficient DA quinone.27 The redox-active prop-
erties of transition metals including Fe, Cu and Zn may potentiate
the oxidation of DA and formation of toxic species associated with
this degradation pathway. Furthermore, the MPTP-induced eleva-
tion of such metals could contribute to the rapid neuron death
cascade observed following insult, accelerating the DA-mediated
cell loss observed in idiopathic PD.
Redox active metals such as Mn have been shown to cause
nigral cell death in a manner mimicking the action of neurotoxins
like MPP+.28 Further, Mn inhibits the activity of tyrosine hydroxy-
lase, the enzyme responsible for the conversion of L-tyrosine to
L-DOPA thus decreasing striatal DA. Mn could also stimulate
reduction of striatal DA concentrations directly through DA auto-
xidation. However, more recent studies29 directly comparing Mn
administration with MPTP insult suggests Mn alone does not
produce comparable neurotoxicity, and that there is no potentiating
eﬀect of Mn when administered 3 weeks prior to MPTP adminis-
tration. Mn exposure did increase astrocyte activity in the globus
pallidus of treated C57BL/6 mice. Paradoxically, Mn administration
for 7 days prior to MPTP insult demonstrated a capacity to increase
DA by up to 60% compared to MPTP treatment alone.30
The conflicting data described here regarding the role of Mn
in mitigating and/or accentuating MPTP toxicity highlights a
significant limitation in generalising the eﬀects of all redox
active metals and the role they play in the toxin’s mode of action.
Redox activemetals are implicated in ROS generation and ultimately
cell death; therefore, pre-treatment of subjects with metals can
significantly alter homeostasis before MPTP insult occurs, poten-
tially complicating interpretation of MPTP as a model for cell death
in PD. In their protocol for producing the MPTP mouse model of
PD, Jackson-Lewis and Przedborski16 insist on experimentally
measuring the impact of drug pre-treatment on MPTP metabolism
(such as assessment of MPP+ levels) when investigating potential
neuroprotective agents, suggesting that if MPTP toxicokinetics are
altered in the pre-treated animal administration of the insult should
be delayed until after MPTP/MPP+ metabolism is established.
This has implications for studying the eﬀects of metals on
MPTP toxicity, as well as for understanding the properties of
metals in arresting MPTP damage. Another example of this is the
conflicting data regarding potential protective properties of Cu
in MPTP treated mice. Cu is noted as a major source of free
radicals in Alzheimer’s disease,31,32 and elevated Cu levels can
increase cellular oxidative load.33 There is some literature
describing how Cu may attenuate MPTP-induced neuronal
death. Mice with supplemented Cu2+ intake (through CuSO4-spiked
drinking water for 30 days prior) displayed dose-dependent
resistance to intracerebroventricular MPP+ administration. Cu
treatment was only eﬀective at reducing MPP+-induced striatal
lipid peroxidation and DA depletion at either a high Cu dose for
chronically-exposed animals, or in animals receiving an acute
intraperitoneal dose 24 hours prior to lesioning.34 Similar
evidence suggesting Cu interferes with induced toxicity was
observed in rats given intraperitoneal CuSO4 injections prior to
MPP+ administration, where attenuation of the neurotoxin was
measured by reduced TH inactivation, less protein nitration and
marked retention of striatal DA in the lesioned animals.35 Again,
it is diﬃcult to directly associate Cu pre-treatment with any
potential neuroprotection against MPTP and MPP+ due to the
myriad of cellular processes influenced by drastically altering Cu
homeostasis. Elevated extracellular Cu has been shown to
disrupt DA metabolism without any external neurotoxin in a
neuroblastoma cell line through inhibition of transmembrane
proton pumps required for active DA transport.36 Duncan and
White37 suggested that oral Cu intake prior to neurotoxin
exposure may mitigate the redox activity of Fe and MPTP (see
following section) through competitive uptake in the intestinal
tract. Priority should be given to investigating the eﬀect of rapid
influx of Cu on the neuron’s metal traﬃcking systems, especially
considering the known implications of altered Fe metabolism
in human PD. Decreased Cu levels have been observed in
MPTP-lesioned animals with no Cu-chelating pre-treatment or
Cu supplementation. Both Cu and Mn have displayed marked
decreases in striatal regions of MPTP-treated mice, with Cu
exhibiting a near-halving of total content in the midbrain.38
The changes in Cu concentrations observed in MPTP treated
cells are not necessarily reflective of Cu changes in human PD.
In fact, the ambiguity in data describing post-lesioning Cu
levels reflects the limited knowledge of Cu metabolism in
idiopathic PD in humans.6,8 Compared to Fe, relatively little
is known about perturbations in Cu metabolism in PD.
Pall et al.39 observed an increase in cerebrospinal fluid Cu
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concentrations in 24 idiopathic PD patients compared to a
34-strong control group, possibly explaining reduced ferroxidase
activity from Cu-binding ceruloplasmin observed in a later study
of PD cases.40 Imaging of Cu distribution in MPTP lesionedmice
brains found decreased Cu in periventricular regions up to
7 days after administration, which either returned to or exceeded
pre-dosing levels 28 days following.41 However, the role of Cu in
PD pathogenesis may be independent of the cell death observed
following MPTP intoxication; Cu has been shown to play a role in
the aggregation of insoluble a-synuclein-based Lewy bodies,42 a
feature observed in human PD that is not mirrored in MPTP
models.43,44 If Cu-mediated Lewy body formation is indeed one
of the major pathways through which altered Cu metabolism
contributes to neuron loss in PD, interpretation of data describ-
ing changes in Cu levels following MPTP should take this into
account. As with all metals, the various roles of Cu in numerous
cellular processes do somewhat limit decisive conclusions that
can be drawn from experimental data when comparing human
disease states to animal models.
Does iron metabolism following MPTP insult
reflect changes in PD?
Iron has been implicated more than any other redox active
metal in PD pathogenesis. Since Lhermitte’s early observations
of 1924,4 significant attention has been given to elucidating the
role of Fe in neuron death. Typical features of generalised Fe
overload in the cell closely mirror those observed in PD,
including increased ROS production, decreased activity of
antioxidant proteins and inhibition of mitochondrial enzymes,
including complex I.45 Importantly, numerous biochemical
characteristics of Fe overload are also present following MPTP
administration.
A proposed mechanism of Fe-mediated MPTP neurotoxicity
is presented in Fig. 1. In vitro studies of MPTP in astrocyte
cultures found that glial conversion to MPP+ by MAO activity is
the primary method of bioactivation, but redox-active Fe also
contributes to the formation of the toxic metabolite.46 MPP+ is
released into the cytosol and taken up into neurons via the
dopamine transporter (DAT), where it accumulates and stimu-
lates cellular dysfunction and death by mitochondrial failure
(by way of inhibition of mitochondrial complex I) and increased
oxidative stress (the theorised pathway involving Fe).47 Thus,
the role of Fe in MPTP-induced cell loss appears to be multi-
dimensional: Fe is not only involved in the production of
cytotoxic species through metal-mediated O2
 production, but
also in the generation of the toxic moiety MPP+ from its parent
MPTP molecule. Further evidence for the role of Fe in MPTP
toxicity has been uncovered at the genetic level. Gene expres-
sion profiling of MPP+-exposed MN9D dopaminergic cells
found 51 genes that exhibited a significant response to the
Fig. 1 Proposed mechanism for Fe-mediated neurotoxicity of MPTP. MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPP+ = 1-methyl-4-phenylpyridinium,
MAO = monoamine oxidase, APP = amyloid precursor protein, DAT = dopamine transporter protein, DMT1 = divalent metal transporter protein 1, TfR = transferrin
receptor, HO-1 = heme oxygenase-1.
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toxin compared to control, with known functions including
apoptosis, cellular metabolism, signal transduction and oxidative
stress. Using Gene Ontology for Function Analysis (GOFFA), a
functional tree of gene expression related to Fe binding was
deduced. All six of the identified genes were down regulated,
four of which were associated with oxidative stress (Cdo1, P4ha1,
Rrm2, Tbxas1),48 highlighting the suspected role of Fe in
increased oxidative damage arising from MPP+ toxicity. Inter-
estingly, many of these genes are also activated in idiopathic
Parkinson’s disease.49–51
MPP+ is highly eﬃcacious at stimulating DA release, resulting
in a marked increase in striatal hydroxyl radical (OH) concen-
trations that can be arrested by DA-depleting drugs such as
reserpine. Additional hydroxyl species are sourced through
MPP+ induction of nitric oxide synthase mechanisms.52 This
eﬄux of dopamine increases MAO-A and -B activity, with
increased DA deamination producing elevated levels of H2O2.
Fe-mediated Fenton chemistry in the cell ensures continued
production of hydroxyl radicals by oxidation of Fe2+ in the
presence of H2O2, while constantly regenerating through
reduction with the same H2O2 species. Increasing the amount
of striatal Fe available increases the formation of OH53 and
other products of dopamine autoxidation, contributing to the
cell’s overall oxidative load. Assuming a modest source of Fe is
available, this reaction continues, overwhelming cellular anti-
oxidant mechanisms and inducing cell death.
MPTP administration has demonstrated an eﬀect on labile
Fe pools by increasing levels of free Fe in the dopaminergic
pathway. Both ferric (Fe3+) and ferrous (Fe2+) species were
observed to increase in the SN of unilaterally lesioned African
green54 and macaque monkeys.55,56 The source of changes in
the labile Fe pool in PD and the oxidation state of Fe species
involved is an obvious target for determining the aetiology of
the disease. A potential candidate for elevated brain Fe levels is
via the storage protein ferritin. Ferritin contains 24 subunits,
consisting of H-units (heavy chain) with ferroxidase activity to
convert toxic Fe2+ to manageable Fe3+ species, and L-units (light
chain), which promote ferrihydrite formation for storage. Selec-
tive elevation of ferritin levels in transgenic mice has been shown
to oﬀer some degree of neuroprotection against MPTP-induced
neuron death,57 though interestingly chronic ferritin expression
in dopaminergic neurons resulted in older animals showing
more susceptibility to MPTP neurotoxicity.58 Unilateral lesioning
of monkeys with MPTP stimulated a bilateral increase in ferritin
expression in the pallidum and SN pars reticulata.59
If ferritin’s ability to appropriately handle Fe is compro-
mised, the vast Fe stockpile (fully assembled ferritin can store
up to 4500 Fe3+ ions) can present a major source of redox-active
material. Mutation to the gene producing ferritin L-units
produces ferritin species with a predisposition to causing
oxidative damage through Fe mishandling.60 Accumulation of
ferritin following MPTP exposure does not necessarily reduce
the labile Fe pool within the cell if the capacity of the protein to
store Fe is reduced. Oxidative damage aﬀecting Fe storage
capacity of the ferritin molecule itself has been demonstrated
in vitro, where incubation of apoferritin with the heme
precursor 5-aminolevulinic acid resulted in a 61% decrease in
Fe uptake following exposure.61 MPTP lesioning of mice eli-
cited a decrease in H-unit ferritin that resulted in an increase in
labile Fe3+ in the SN.62 Paraquat, a cation that displays similar
structural properties to MPP+, promotes complete release of Fe
from ferritin, though electron spin resonance spectroscopy
showed paraquat did not induce structural deformities in
ferritin chains and that the protein regained the ability to
reincorporate Fe into its structure.63
Ferritin levels in PD have not demonstrated a clear increase
in expression, rather changes observed in idiopathic PD are
somewhat ambiguous.64 Nigral ferritin immunoreactivity has
been described as decreasing (with a corresponding increase in
total Fe, suggesting Fe storage capacity may be compromised)6
and increasing (with corresponding increase in Fe3+, suggesting
ferritin expression may be in response to elevated Fe)65,66 in PD.
The significance of ferritin in Fe metabolism is clear, and the
role it plays in cell death mechanisms found in both MPTP
toxicity and idiopathic PD is undoubtedly of great importance
in elucidating PD pathogenesis. However, it is uncertain if
ferritin’s role in PD progression is contributory to cell death
or reactionary, as part of the cell’s defence mechanism.
Interaction between ferritin and MPTP may still hold key
information regarding the risk factors of elevated Fe in the
aging brain. MRI analysis of ferritin in the human brain in vivo
suggested ferritin levels increase in the caudate, putamen,
globus pallidus, thalamus and hippocampus (but decreased
in the frontal lobes) with age.67 Ferritin accumulation in the SN
of human PD brains appears confined to glia.68 One theory
supporting age-related changes in ferritin-accumulating cells
and associated Fe toxicity is the ability of ferritin to release Fe2+
in response to elevated O2
 levels.69 Hence, accumulation of
ferritin with age could indeed provide a viable source of Fe for
the increasing labile Fe pool, entering neurons via microglial
activation and uptake through divalent metal transporter-1
(DMT1) on the neuronal membrane. A lack of ferritin up-regulation
in SN neurons of human PD cases may explain the increases in
available brain Fe and heightened susceptibility to neuron loss
with age.70 Disruption of ferritin expression or activity in the
neuron may limit the cell’s practical defences against sudden
Fe influx, increasing the labile Fe pool and causing oxidative
damage. Thus, alterations in ferritin levels occurring with age
have a direct eﬀect on nigral Fe and susceptibility to Fe-related
oxidative stress that occurs in the aging brain.
MPTP has been employed to study the possible influence of
this progressive change in brain Fe. Histochemical study of Fe
deposits in two age groups of macaque monkeys given a single
unilateral MPTP injection found that dense, focal deposits of Fe
were only observed in the SN of older (>7 years) monkey and no
significant variation in MPTP-induced neuron loss was obvious
between the two groups. The Fe deposits were observed
bilaterally, with the authors suggesting this was indicative of
Fe deposition prior to lesioning71 though, as previously noted,
unilateral MPTP lesioning in monkeys has resulted in
increased bilateral ferritin expression.59 Neonatal Fe feeding
of mice has been used to model age-related changes in Fe,72
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and in conjunction with noradrenaline denervation by N-[2-
chloro-ethyl]-N-ethyl-2-bromobenzylamine (DPS4), near total
abolition of spontaneous motor activity with no restorative
eﬀects observed after administration of L-DOPA was observed
in Fe-loaded, MPTP treated mice.73 This suggests that increas-
ing amounts of brain Fe, as is the case with aging, can cause
vulnerability in both the dopaminergic and noradrenergic
pathways, with denervation of noradrenaline potentiating
MPTP toxicity following Fe overload. Again, it is important to
consider the implications pretreatment of animals might have on
other cellular metal regulation systems prior to MPTP/MPP+
metabolism being established. However, unlike the observed
ambiguity surrounding Cu pretreatment, Fe loading of mice
clearly enhances MPTP toxicity,74 and when considered in con-
junction with evidence of increased brain Fe with age presents a
practical picture of how Fe contributes to oxidative damage in PD.
Dietary Fe control has also been used in mice to demon-
strate its role in DA synthesis and susceptibility to oxidative
damage through DA toxicity. Mice fed a Fe-deficient diet
showed decreased striatal DA content compared to mice fed a
normal diet, possibly due to insuﬃcient Fe needed for TH
synthesis. Interestingly, Fe deficient mice did not display DA
reduction or motor deficiencies compared to control animals
following acute MPTP exposure,75 suggestive of the influence
that an increased labile Fe pool may have on DA autoxidation.
Elevated free Fe may not necessarily be a direct cause of
increased free radical production; rather unbound Fe may
result from other pathways such as an increase in activity of
heme oxygenase-1 (HO-1) in response to brain injury. HO-1
catalyses degradation of heme to biliverdin, which is sub-
sequently metabolised to bilirubin, CO and free Fe. In PC-12
cells treated with MPP+ HO-1 induction was observed to rapidly
increase in line with ROS production. Inhibition of HO-1 by
zinc protoporphyrin-IX resulted in a marked increase in ROS
production, indicating HO-1 may play a cytoprotective role
against MPP+-induced toxicity.76 This suggests elevated free
Fe post-MPP+ (and thus MPTP) exposure could stem from
increased heme degradation. Conversely, Lee et al.77 described
increased HO-1 expression brought about by administration of
an Fe-dependent prolyl hydroxylase enzyme inhibitor helped
attenuate nigral Fe accumulation following MPTP exposure.
3,4-Dihydroxybenzoate upregulated neuronal expression of the
HIF-1a gene, increasing cellular HO-1 levels and returning
nigral Fe concentration to near control levels. Innamorato
et al.78 recently used MPTP-lesioned Nrf2- (master regulator
of antioxidant response elements) and HO-1- (target gene of
Nrf2) null mice to demonstrate that both knockout mice
displayed equivalent Fe deposition in the SN compared to
lesioned wild-type animals, suggesting HO-1 and associated
antioxidant response elements do not contribute to Fe accu-
mulation or traﬃcking in MPTP induced cell death.
Variation in tau protein and Fe concentrations were also
observed inMPTP lesioned mice. Tau is a microtubule-associated
protein that is linked to a variety of neurodegenerative disorders,
termed tauopathies. Modifications to tau, such as phosphoryla-
tion and glycosylation are thought to play a major role in tau
mediated neuronal toxicity.79 A possible mechanism demonstrat-
ing tau involvement in Fe traﬃcking has been proposed, where
tau contributes to amyloid precursor protein (APP) surface activ-
ity. APP has ferroxidase activity,80 where it interacts with
membrane ferroportin to shunt Fe from the cell. Loss of tau in
primary cell cultures resulted in marked Fe accumulation. Simi-
larly, in MPTP treated mice a decrease in tau levels was observed
in the SN three days after acute dosage, remaining suppressed
until day forty-five post treatment, with a corresponding increase
in nigral Fe.81 In human PD, oxidation of ceruloplasmin, a
Cu-binding ferroxidase protein, has shown a similar eﬀect of
reducing cellular Fe export leading to increased Fe retention.82
Fe is transported into neurons through either delivery by
transferrin (Tf) to membrane receptors or via DMT1.83 DMT1
facilitates the rapid transfer of Fe from the extracellular spaces
into the cytoplasm, as either free Fe2+ or by mediation of a ferric
reductase enzyme.84 Decreased ferroportin, in addition to
increased levels of DMT1 have been observed in the SN dopa-
minergic neurons of MPTP-treated mice, with corresponding Fe
accumulation, though not in similar neurons of the adjacent
ventral tegmental area (VTA).85 Increased expression of DMT1
has also been reported in the SNpc of human PD samples, in
line with an observed elevation in DMT1 expression in MPTP
intoxicated mice.86 It is still unclear as to why DA neurons in
the VTA of mice are resistant to MPTP challenge yet adjacent
neurons in the SNpc are vulnerable, though recent evidence
suggested that VTA neurons demonstrate a functional genetic
response to MPTP insult including ion/metal regulatory genes
(PANK2 and Car4) that is not observed in SNpc DA neurons.87
Increased Fe in at-risk areas of the brain has been exten-
sively described in both idiopathic PD and MPTP models.
Indeed, Fe accumulation is a common theme in various neuro-
logical disorders with parkinsonian pathology, as reviewed by
Berg and Hochstrasser,88 as well as generalised inflammation
in PD.89 While it is apparent that elevated Fe contributes to
MPTP-mediated neuron loss, the precise mechanism by which
Fe stimulates oxidative damage is still not clear; in fact it is
probable that perturbations to Fe regulatory systems within the
cell contribute to the formation of toxic species through
multiple pathways. Commonality between Fe accumulation
and oxidative stress would suggest Fe involvement in neuron
loss is not necessarily a causative factor in PD; however altered
iron metabolism has shown promise as a target for novel
therapeutics, justifying targeting cellular Fe handling as an
import field of study. Regardless, most reports have described
Fe-related factors in isolation, due mostly to the diﬃculties in
observing Fe metabolism as a whole. Improving techniques will
ensure that Fe and MPTP toxicity, and thus PD pathogenesis
will remain a keenly investigated topic for some time.
MPTP stimulates a cellular metallomic
response
Changes to redox-active metal levels in the PD brain may not
directly contribute to elevated levels of oxidative stress; metals
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such as Cu and Zn are also key functional components of
antioxidant proteins (see Fig. 2). The changes in metal levels
observed in MPTP are most likely intertwined: altered Fe levels
induce increased oxidative stress, leading to an influx of metal-
binding proteins (such as superoxide dismutases – SOD) that
scavenge the evolved free radicals, mitigating cell damage.
Major proteins with antioxidant properties include Cu,
Zn- and Mn-SOD and Cu/Zn binding metallothioneins (MTs).
Cellular Zn homeostasis has been implicated as a factor that
may be involved in neurodegenerative processes and diseases,
with Zn ionophores showing eﬃcacy in restoring cognition in
animal models of Alzheimer’s disease.90,91 Increasing concen-
trations of Zn2+ with age may contribute to increased mito-
chondrial ROS formation.92 It is thus not surprising that Zn has
exhibited dyshomeostasis in MPTP models of PD. Mice exposed
to acute doses of MPTP possessed degenerating neurons in the
SNpc that showed an accumulation of cytosolic Zn compared to
saline-treated controls,93 though increased brain Zn may be
more generally indicative of brain trauma.94 Mice administered
moderate amounts of Zn did not display depleted DA levels,
though co-administration of Zn with MPTP significantly
lowered DA, suggesting a possible potentiating eﬀect of Zn on
MPTP toxicity.95 Zn may, however, be indicative of a cellular
response to MPTP injury involving endogenous antioxidant
proteins like Cu,Zn-SOD. 90% of brain Zn is protein-bound, the
remaining 10% of labile Zn is confined to presynaptic vesicles.96
Rojas et al.97 reported that, following MPP+ insult, the number
of Zn-positive terminals decreased in the mouse striatum and
increased in the stratum radiatum and stratum oriens regions
of the CA2 zones of the hippocampus. This eﬄux of Zn could be
indicative of a rapid mobilisation of ionic Zn preceding synth-
esis of MT98 and Cu,Zn-SOD, both antioxidant proteins known
to scavenge free radicals.99 Both of these proteins have shown
biological importance in PD more broadly, and MPTP-induced
toxicity specifically.
SOD-group enzymes are ubiquitous proteins that utilise a
redox-active metal to dismutase O2
 to O2 through reduction,
or to H2O2 through oxidation with the presence of H
+. In
humans, SOD exists as either Mn- or Cu,Zn species, both of
which are found in the brain and show age-related changes.100
Synthetic O2
 mimetics have shown reduced paraquat-induced
neuronal toxicity in both cell cultures and adult mice.101 One
hypothesised mechanism of MPTP action involves selective
nitration of TH. This process is mediated by production of
O2
 that in turn produces peroxynitrite (ONOO), nitrating the
enzyme and rendering it inactive. In mice overexpressing
Cu,Zn-SOD this eﬀect was not observed, suggesting blocking
ONOO formation by scavenging O2
 formation can help arrest
MPTP toxicity.102 MPTP administration itself may stimulate
increased SOD activity; both Cu,Zn-SOD and Mn-SOD demon-
strated a twofold jump in activity in the VTA of treated mice
after 7 days of chronic exposure. Interestingly, only Mn-SOD
Fig. 2 Proposed mechanism for Cu- and Zn-mediated cellular response to MPTP insult. MPP+ = 1-methyl-4-phenylpyridinium, Ctr1 = copper transporter 1, Ztr1 = zinc
transporter 1, DMT1 = divalent metal transporter 1, Cu,Zn-SOD = Cu,Zn superoxide dismutase, MT = metallothionein.
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displayed increased activity in the SN region.103 Increased nigral
Mn-SOD activity was confirmed in additional studies, along with
an observed decrease in SN Cu,Zn-SOD activity following MPTP
lesioning. Pretreatment of mice with 17b-estradiol, a sex hormone,
increased Cu,Zn-SOD and Mn-SOD immunoreactive neurons post-
insult, though not reactive glia.104 Both Cu,Zn-SOD and Mn-SOD
null mice display heightened sensitivity to MPTP lesioning,
whereas mutation to both SOD1 (Cu,Zn) and SOD2 (Mn) genes
demonstrate resistance to the toxin compared to control.20
In human PD, an increase in Mn-SOD mRNA was observed
in line with decreased Cu,Zn-SOD expression in the SN,105
agreeing with decreased Cu,Zn-SOD and increased Mn-SOD
immunoreactivity in the SN of MPTP treated mice.106 Mn-SOD
accounts for around 10% of intracellular SOD isoforms and
is a predominately mitochondrial enzyme. Increased expres-
sion of Mn-SOD is likely indicative of altered oxidative load
arising from mitochondrial dysfunction. In MPTP toxicity, O2

released from mitochondria reacts with nitric oxide (NO) to
form ONOO. Inhibition of NO synthases prevents MPTP toxicity
in baboons;107 thus increased Mn-SOD activity chaperoning
errant O2
 could similarly limit formation of this reactive
nitrogen species (RNS).
MPTP lesioning of common marmosets demonstrated loss
of Cu,Zn-SOD mRNA throughout the basal ganglia, most
marked in the SNpc. This loss of a major antioxidant enzyme
(in conjunction with depletion of glutathione peroxidase in
both the SNpc and SNr) has also been observed in human PD
patients,108 further supporting the hypothesis that metal
dyshomeostasis in MPTP-mediated cell death is indeed reflec-
tive of PD etiology. Little information is available directly
comparing Cu,Zn-SOD activity and total Cu and Zn levels in
either MPTP models or human PD. Analysis of blood taken
from PD patients found red cell Cu,Zn-SOD activity was
increased, as was red cell Cu and Zn, in addition to plasma
Cu levels compared to control donors.109 It is diﬃcult, however,
to infer the significance of altered circulating Cu,Zn-SOD
activity compared to expression in the brain. Correlating
Cu,Zn-SOD and total metal levels is challenging, considering
that these metals are also active components of other metal-
binding proteins. Cu,Zn-SOD is a very active Cu and Zn binder,
and any loss of capacity to uptake free Cu and Zn may increase
intracellular metal levels and thus redox activity.110 However,
the role of other proteins with aﬃnity to Cu and Zn increasing
uptake of metals in direct response to decreased Cu,Zn-SOD
has not been studied and is deserving of attention.
Metallothioneins are a group of 0.5–14 kDa proteins
containing approximately 25–30% cysteine residues111 that
have shown potential protective features in a range of genetic
PD animal models.112 The large sulfur-component of MTs
results in a strong aﬃnity to group 11 and 12 metals, including
endogenous Cu and Zn and heavy metals such as cadmium
(Cd) and mercury (Hg). These cysteine residues are also capable
of chaperoning ROS, removing the threat of cellular damage
through reduction of the harmful species. Like SOD, MTs are
thought to play a role in mitigating oxidative damage through
attenuation of ONOO synthesis.113 While metal ions do not
play a direct role in ROS or RNS removal by MTs, the mere
presence of elevated metal concentration can induce MT
expression. In SK-N-SH cell lines grown in Zn-rich media
increased MT expression help prevent cell death from metha-
mphetamine toxicity.114,115 Induction of MT expression by
exposure to Cd and dexamethasone (a known MT induction
factor) five hours prior to MPTP insult resulted in increased DA
levels compared to non-induced animals.116 However, there is
some contention regarding the role of MT isoforms following
MPTP neurotoxicity. Rojas and Klaassen117 reported that the
DA denervation by MPTP was not attenuated in MT knock-out
mice. MT expression was, however, observed to decrease in the
striatum of mice in response to a MPP+ challenge;118 this
observation was supported by data demonstrating a reduction
in MT-1 mRNA.119,120 Unfortunately, relatively little information
is present in literature describing changes in MT levels in the PD
brain. Further study into how MTs are expressed and distributed
in the human dopaminergic pathway is required.
In addition to its role in promoting oxidative stress through
changes to the labile Fe pool, other metalloenzymes also rely
upon Fe for activity. TH uses O2, tetrahydrobiopterin and Fe as
cofactors in its role in DA synthesis. Loss of TH activity
precludes DA conversion from L-DOPA, accounting for marked
DA decrease following MPTP administration. Monkeys given
an MPTP insult displayed decreased TH mRNA compared to
unlesioned animals.121 In human PD, surviving dopaminergic
neurons have shown similar decreases in TH mRNA levels.122
Metal chelators arrest MPTP and MPP+
neurotoxicity
If the hypothesised changes in the labile Fe pool are a direct
cause of increased oxidative stress in PD (and the MPTP
model), it would thus stand to reason that modulation of redox
active metals like Fe may aid in reducing the impact of sudden
metal dyshomeostasis.
3-Hydroxypyridine-4-one (deferiprone) has shown in vitro
neuroprotective properties against a range of oxidative stress
stimuli, including MPP+, amyloid beta (Ab), H2O2 and Fe
3+ in
neuroblastoma SHSY-5Y cells.123 Active metal chaperones like
the orally bioavailable and blood–brain barrier-permeable
5-chloro-7-iodo-8-hydroxyquinoline (clioquinol) and associated
8-hydroxyquinoline analogues have shown potential as thera-
peautics for several neurodegenerative disorders,124 even so far
as to demonstrate applicability in restoring cognition in animal
models of Alzheimer’s disease90 and improving executive func-
tion in human clinical trials.125 In clioquinol-treated animals
given acute MPTP doses, increases in markers of oxidative
stress and corresponding decreases in cellular antioxidants
normally seen following MPTP leisoning were not observed.57
5-(N-Methyl-N-propargyaminomethyl) 8-hydroxyquinoline, or
M30, is a Fe-ionophore that also shows MAO-A and -B inhibitory
properties. Acute and chronic dosing of animals with M30
results in the expected hallmarks of MAO inhibition, inclu-
ding increased DA, serotonin and noradrenaline levels, and
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corresponding decreases in monoamine metabolites. Adminis-
tration of M30 at the time of MPTP insult resulted in attenuated
DA depletion.126 M30 may attenuate the eﬀects of MPTP when
concurrently administered in two possible ways: by either
inhibiting MAO-B mediated conversion of MPTP to MPP+ in
glia; or by chelating free Fe required for MPTP oxidation, both
of which disrupt MPTP metabolism. Oral administration of
M30 for 14 days following MPTP insult was shown to oﬀer some
degree of restitution to nigrostriatal dopaminergic neurons,
with increased striatal DA levels and a restoration of transferrin
receptors (TfR) in the SNpc to within 20% of control levels.
Increased DA levels are again indicative of MAO inhibition, and
increased TfR-positive cells observed in M30-only treated animals
were found in similar numbers in MPTP treated animals,
suggesting Fe-chelation by M30 aﬀects Fe transfer in and out
of cells via Tf.127 The MAO inhibitory properties of 8-hydroxy-
quinoline compounds stem from the N-propargyl group
common to clinical anti-Parkinson’s drugs rasagiline and
selegiline.128 Selegiline has shown significant eﬀectiveness in
both protecting against MPTP toxicity (as does rasagiline)129
and slowing PD progression in human trials.130 While MAO
inhibition may prevent both MPTP to MPP+ conversion in
animal models, as well as limiting DA autoxidation in human
PD, interaction with metal metabolism may be present. Selegi-
line has been suggested to both promote SOD expression, and
limit Fe-mediated DA oxidation in several models of PD,
including MPTP,131 which may reflect a partial mode of action
for the compound in humans independent of MAO inhibition.
R-Apomorphine is a MAO inhibitor and dopamine D1–D2
receptor agonist that has demonstrated similar eﬀectiveness to
L-DOPA as a treatment for PD in humans.132 In addition to its
aﬃnity to dopamine receptors, R-apomorphine is also an
eﬀective free radical scavenger and Fe-chelator that, when
concurrently administered to mice with MPTP, showed possible
neuroprotective features suggestive of antioxidant properties,
as opposed to impeding MPP+ formation through MAO inhibi-
tion.133 Ginsenoside Rg1, an active component of ginseng root
has shown potential beneficial properties in pretreated mice
exposed to MPTP. Rg1 treated animals displayed lower Fe-positive
cell densities following MPTP administration, with decreased
DMT1 and increased ferroportin expression, indicative of a
shift towards pre-toxin Fe traﬃcking mechanisms.134 Similar
eﬀects were observed in Rg1 pre-treated MES23.5 cells exposed
to MPP+.135
The Fe3+ chelator deferrioxamine (also known as desferal
and desferrioxamine) has shown conflicting data regarding its
role in either potentiating or preventing MPTP toxicity. In MPP+
treated rats, deferrioxamine was shown to enhance the
formation of hydroxyl radicals in the striatum.136 Conversely,
pretreatment of SK-N-SH dopaminergic neurons in culture with
deferrioxamine and coenzyme Q10 (an antioxidant enzyme) was
shown to reduce the impact of Fe loading.
Administration of diethyldithiocarbamate, a Cu chelator, to
mice treated with MPTP resulted in potentiation of MPTP
neurotoxicity with corresponding DA depletion and increased
astrocyte activity at the site of lesion.137 Cu-chelation does not
necessarily result in MPTP potentiation; D-penicillamine (used
to chaperone Cu in Wilson’s disease) did not increase striatal
DA depletion as diethyldithiocarbamate did; instead it showed
some, albeit modest, prevention of MPTP-induced dopamine
loss.138 For further information, a range of Cu complexing
agents was recently review by Duncan and White.37
Chaperoning of metals via chelating or ionophoric com-
pounds has shown great potential as viable therapeutics for
treating neurodegenerative diseases, which is reflected by the
range of compounds studied within the context of MPTP-
induced neuron loss (Table 1). Thus, the importance of prop-
erly elucidating the role of metals in PD and the suitability of
MPTP as a model for metal-based neurodegeneration is integral
to the development of next generation chelators and ionophores.
Metals and alternative parkinsonian toxins
Widespread use of MPTP to model PD is due not only to its
clinically indistinguishable recapitulation of parkinsonism in
humans and non human primates, but also its comparatively
simpler method of administration compared to other neuro-
toxins.16 However, distinct diﬀerences in the mode of toxicity of
MPTP and alternative nigral insults cannot be disregarded
when discussing the appropriateness of MPTP as a model for
PD, particularly in relation to relating disease progression to
metal metabolism.
6-Hydroxydopamine (6-OHDA) is a catecholamine with
selective toxicity shown towards both DA and noradrenergic
neurons.139 Administration of 6-OHDA is somewhat more
complicated; requiring stereotaxic injection of 6-OHDA into
the nigra itself, medial forebrain bundle or caudate-putamen
to produce the desired lesion of the nigrostriatal pathway.140
A major advantage of 6-OHDA over MPTP is the reported ability
of the toxin to produce limited eﬀects on the contralateral side,
and a controllable loss of dopamine in the ipsilateral hemi-
sphere.141,142 Controlled administration of 6-OHDA to only the
nigrostriatal pathway, whilst leaving the mesolimbic pathway
unaﬀected produces a lesion that is reflective of the pattern of
cell loss observed in idiopathic PD.143
Bilateral elevation in nigral Fe following unilateral 6-OHDA
administration has been observed, though significant retention
of Fe at the site of injection was also still observed 21 days post-
lesion.144 Three-dimensional reconstruction of Fe distribution
surrounding the SN using laser ablation-inductively coupled
plasma-mass spectrometry (LA-ICP-MS) imaging found that
this artefact arising from the lesioning procedure did not
contribute to nigral Fe levels,145 thoughmost common analytical
techniques for measuring metals lack the spatial specificity to
resolve these sources of Fe. Ultrasound analysis of Fe in the SN
of lesioned rats has also shown an increase Fe levels.146
Significant unilateral reduction in striatal Fe and Cu and
increase in periventricular Cu, measured by LA-ICP-MS, has
also been reported 42 days after 6-OHDA administration.147
The eﬀect of 6-OHDA on metal metabolism in the nigros-
triatal pathway does mirror MPTP in some key features. In cell
culture down-regulation of ferroportin following 6-OHDA insult
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may contribute to Fe accumulation,148,149 as may a similar
up-regulation of DMT-1.150 6-OHDA also elicits a similar
up-regulation ofMT levels following exposure.151 Some interesting
diﬀerences between the two toxins do exist; cell culture studies
of Fe3+ and Cu2+ potentiation of 6-OHDA in SH-SY5Y cells
found Cu accelerated 6-OHDA auto-oxidation and promoted
metal-mediated DNA damage to a greater degree than Fe
alone.152 Iron release from ferritin following 6-OHDA adminis-
tration appears to subsequently accelerate autoxidation of the
toxin.153 SOD-1 itself directly inhibits 6-OHDA autoxidation by
up to 96% in vitro.154 Several metal chelators show similar eﬀects in
arresting toxicity as those used in MPTP research, including VK-28,
an 8-hydroxyquinoline analogue,155 and Rg1.156 Desferrioxamine-
pretreated rats showed significant protection against 6-OHDA-
induced DA loss,157 as did deferiprone.158
As mentioned previously, rotenone and paraquat (1,10-
dimethyl-4,40-bipyridinium) are two commercial pesticides with
structurally similarities to MPTP and MPP+. The primary
mechanism of rotenone toxicity also involves complex I inhibition,
and pathological features of rotenone neurotoxicity include the
presence of Lewy body-like cytoplasmic inclusions containing
ubiquitin and a-synuclein,159 which is an important feature of
idiopathic PD not reflected in the MPTP paradigm. Paraquat
does not directly interact with the mitochondrial electron
transport chain, instead it partakes in redox cycling to produce
the same increase in oxidative stress.160 Relatively sparse
information is available regarding the role of metals in rote-
none and paraquat toxicity and how it relates to PD. Cerulo-
plasmin-null mice exposed to a low dose of rotenone over 28
days showed a significant eﬀect on motor behaviour, pathology
and oxidative stress markers compared to wild types,161
suggestive again of antioxidant properties of the Cu ferroxidase
protein. Rotenone also increases H-ferritin mRNA and protein
synthesis in NIH3T3 fibroblasts and SH-SY5Y neuroblastoma
cells.162 Direct comparison of paraquat and MPP+ toxicity in
cell culture found that both molecules have a similar deleter-
ious impact on cellular mRNA and protein expression related to
intracellular iron transport. Paraquat toxicity is sometimes
coupled with administration of complex III inhibitor maneb
(manganese ethylene-bis-dithiocarbamate) to produce a modest,
yet consistent lesion of the nigrostriatal pathway with minimal
damage to surrounding regions.163
Lactacystin is a relatively new alternative to MPTP for
modelling PD in animals, stemming from concern regarding
the failure of MPTP to reproduce all pathological features of
PD. Lactacystin is a potent proteosomal inhibitor that, when
injected directly into the SN reduces striatal DA and induces
motor dysfunction in rats, as well as replicating Lewy-body
formation in the cytoplasm by impairing the ubiquitin protea-
some system (UPS),164,165 though it lacks the consistency of the
lesion produced by MPTP. Iron regulatory gene profiling of cells
exposed to lactacystin found evidence that the toxin promotes
TfR expression, but not DMT-1 and mitochondrial Fe regulatory
proteins as with MPP+.166 Lactacystin-exposed MES23.5
cells also demonstrated H-unit ferritin and increased labile
Fe,167 mirroring the eﬀects of protracted MPTP exposure.
Genetic overexpression of H-unit ferritin was shown to reduce
lactacystin-mediated DA depletion and neuron loss.168 As is the
case with MPTP, several Fe chelators have shown some degree
of protection and rescue in animals exposed to lacatcystin,
including the 8-hydroxquinilone M30169 and desferriox-
amine,170 suggesting Fe is also integral in the mode of action
of lacatacystin.
Chronic co-administration of MPTP and probenecid (MPTP/P;
4-(dipropylsulfamoyl)benzoic acid) is often used to enhance
nigrostriatal damage by inhibiting the urinary and neuronal
excretion of toxic MPTP metabolites.171,172 MPTP/P retains the
hallmarks of traditional MPTP lesioning, whilst also producing
proteinaceous inclusions with a-synuclein and ubiquitin
immunoreactivity in both the SN and cortex.173 This emerging
model presents an intriguing possibility to study the metallo-
biology of PD in a system exhibiting both Fe elevation and
metal–protein aggregation. Copper was recently shown to play a
role in ubiquitin aggregation in vitro.174 Whilst ubiquitin
accumulation is not unique to Parkinson’s disease,175 this toxin
model provides a more complete picture of both PD pathology,
as well as metal-mediated neurodegeneration.
Conclusion
MPTP remains the most commonly used model for preclinical
testing of new therapies for PD, as well as playing an important
role in investigating the mechanisms of dopaminergic neuron
loss.16 Most research into MPTP metallobiology tends to examine
factors in isolation, rather than investigating the eﬀect of altered
metal homeostasis on the multitude of intersecting pathways that
are relevant to the pathogenesis of PD. As such, there are several
examples where interpretation of changes in metal content follow-
ing MPTP administrationmay not be truly indicative of the toxin’s
mode of action, and thus not representative of idiopathic PD.
This does not, however, discredit the use of MPTP as a viable
PD model for studying metal-mediated cellular response.
Significant evidence points to an apparent dual mechanism
of toxicity for MPTP, through both complex I inhibition and
increasing the labile Fe pool in the cell. These changes in
harmful Fe levels appear to mirror the alterations in Fe
observed in human PD cases, as do the changes in expression
of important metal-binding enzymes, including Cu,Zn-SOD and
Mn-SOD. Several therapeutic agents that have shown potential
in treating PD have a mechanism of action that is also attrib-
uted to an aﬃnity for redox-active metals, which has been
shown in MPTP models of disease.
A major barrier to building a comprehensive picture of
metallobiology in PD stems from the ubiquity of the very metals
implicated in the disease, in that their varied roles and func-
tions are diﬃcult to study in toto. Viewing each metal-mediated
process in isolation cannot account for the knock-on eﬀects of
altered metal homeostasis. Further development of more
holistic systems biology approaches to studying metal metabo-
lism will help better understand not only MPTP as a model for
PD, but cell metallobiology as a whole.
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